{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T03:30:36Z","timestamp":1790566236929,"version":"4.1.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T00:00:00Z","timestamp":1704758400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T00:00:00Z","timestamp":1704758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose of Review<\/jats:title>\n                <jats:p>This review presents recently published clinical trial data and ongoing investigations regarding the treatment of Richter\u2019s transformation (RT).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Recent Findings<\/jats:title>\n                <jats:p>Recently, numerous approaches have been investigated for the treatment of RT including: traditional chemoimmunotherapy regimens combined with targeted agents such as BTKi and BCL2i; immunotherapy combined with targeted agents; non-covalent BTKis; bispecific T cell engagers; and CART therapy. In addition, various novel targeted agents are currently being studied for the treatment of RT in phase 1 and 2 clinical trials.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Summary<\/jats:title>\n                <jats:p>Standard of care treatment with chemoimmunotherapy for RT has limited efficacy in achieving durable remissions. Here, we review recent data on the use of combination treatments and targeted agents in RT. Although some progress has been made in the investigation to optimize treatment of RT, further study is needed to evaluate long term outcomes of recently published trials and test efficacy of upcoming novel agents.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11899-023-00721-8","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T09:02:09Z","timestamp":1704790929000},"page":"45-55","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Treatment of Richter\u2019s Transformation with Novel Therapies"],"prefix":"10.1007","volume":"19","author":[{"given":"Amneet","family":"Bajwa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alma","family":"Habib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam S.","family":"Kittai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,9]]},"reference":[{"issue":"15","key":"721_CR1","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1200\/JCO.2005.05.0187","volume":"24","author":"AM Tsimberidou","year":"2006","unstructured":"Tsimberidou AM, O'Brien S, Khouri I, Giles FJ, Kantarjian HM, Champlin R, et al. Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol. 2006;24(15):2343\u201351.","journal-title":"J Clin Oncol"},{"issue":"3","key":"721_CR2","doi-asserted-by":"publisher","first-page":"765","DOI":"10.3324\/haematol.2019.224121","volume":"105","author":"Y Wang","year":"2020","unstructured":"Wang Y, Tschautscher MA, Rabe KG, Call TG, Leis JF, Kenderian SS, et al. Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center. Haematologica. 2020;105(3):765\u201373.","journal-title":"Haematologica."},{"issue":"3","key":"721_CR3","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1182\/blood.V78.3.797.797","volume":"78","author":"V Pistoia","year":"1991","unstructured":"Pistoia V, Roncella S, Di Celle PF, Sessarego M, Cutrona G, Cerruti G, et al. Emergence of a B-cell lymphoblastic lymphoma in a patient with B-cell chronic lymphocytic leukemia: evidence for the single-cell origin of the two tumors. Blood. 1991;78(3):797\u2013804.","journal-title":"Blood."},{"issue":"10","key":"721_CR4","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1002\/ijc.30263","volume":"139","author":"P Klener","year":"2016","unstructured":"Klener P, Fronkova E, Berkova A, Jaksa R, Lhotska H, Forsterova K, et al. Mantle cell lymphoma-variant Richter syndrome: detailed molecular-cytogenetic and backtracking analysis reveals slow evolution of a pre-MCL clone in parallel with CLL over several years. Int J Cancer. 2016;139(10):2252\u201360.","journal-title":"Int J Cancer"},{"issue":"6","key":"721_CR5","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1111\/bjh.12458","volume":"162","author":"SA Parikh","year":"2013","unstructured":"Parikh SA, Rabe KG, Call TG, Zent CS, Habermann TM, Ding W, et al. Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients. Br J Haematol. 2013;162(6):774\u201382.","journal-title":"Br J Haematol"},{"issue":"12","key":"721_CR6","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1182\/blood-2010-09-302174","volume":"117","author":"D Rossi","year":"2011","unstructured":"Rossi D, Spina V, Deambrogi C, Rasi S, Laurenti L, Stamatopoulos K, et al. The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood. 2011;117(12):3391\u2013401.","journal-title":"Blood."},{"issue":"2","key":"721_CR7","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/(SICI)1096-8652(199902)60:2<99::AID-AJH3>3.0.CO;2-T","volume":"60","author":"SM Ansell","year":"1999","unstructured":"Ansell SM, Li CY, Lloyd RV, Phyliky RL. Epstein-Barr virus infection in Richter's transformation. Am J Hematol. 1999;60(2):99\u2013104.","journal-title":"Am J Hematol"},{"issue":"6","key":"721_CR8","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1111\/bjh.18352","volume":"198","author":"C Favini","year":"2022","unstructured":"Favini C, Talotta D, Almasri M, Andorno A, Rasi S, Adhinaveni R, et al. Clonally unrelated Richter syndrome are truly de novo diffuse large B-cell lymphomas with a mutational profile reminiscent of clonally related Richter syndrome. Br J Haematol. 2022;198(6):1016\u201322.","journal-title":"Br J Haematol"},{"issue":"1","key":"721_CR9","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41591-022-02113-6","volume":"29","author":"EM Parry","year":"2023","unstructured":"\u2022 Parry EM, Leshchiner I, Gui\u00e8ze R, Johnson C, Tausch E, Parikh SA, et al. Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome. Nat Med. 2023;29(1):158\u201369. In this paper, Dr. Parry et al describe how RT transforms from CLL, deepening our understanding of the transformationm process.","journal-title":"Nat Med"},{"issue":"15","key":"721_CR10","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1182\/blood-2013-03-489518","volume":"122","author":"E Chigrinova","year":"2013","unstructured":"Chigrinova E, Rinaldi A, Kwee I, Rossi D, Rancoita PM, Strefford JC, et al. Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. Blood. 2013;122(15):2673\u201382.","journal-title":"Blood."},{"issue":"2","key":"721_CR11","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/j.1365-2141.2008.07166.x","volume":"142","author":"D Rossi","year":"2008","unstructured":"Rossi D, Cerri M, Capello D, Deambrogi C, Rossi FM, Zucchetto A, et al. Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome. Br J Haematol. 2008;142(2):202\u201315.","journal-title":"Br J Haematol"},{"issue":"18","key":"721_CR12","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1182\/blood-2013-11-536169","volume":"123","author":"L Falchi","year":"2014","unstructured":"Falchi L, Keating MJ, Marom EM, Truong MT, Schlette EJ, Sargent RL, et al. Correlation between FDG\/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia. Blood. 2014;123(18):2783\u201390.","journal-title":"Blood."},{"issue":"1","key":"721_CR13","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/ajh.26755","volume":"98","author":"AS Kittai","year":"2023","unstructured":"\u2022 Kittai AS, Huang Y, Beckwith KA, Bhat SA, Bond DA, Byrd JC, et al. Patient characteristics that predict Richter's transformation in patients with chronic lymphocytic leukemia treated with ibrutinib. Am J Hematol. 2023;98(1):56\u201365. This is one of the only studies that evaluated RT that had developed on small molecule inhibitors. Highlighting important clinical indications to consider RT development, and poor overall survival even in the era of modern therapy.","journal-title":"Am J Hematol"},{"issue":"19","key":"721_CR14","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1182\/bloodadvances.2017007302","volume":"1","author":"CR Miller","year":"2017","unstructured":"Miller CR, Ruppert AS, Heerema NA, Maddocks KJ, Labanowska J, Breidenbach H, et al. Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib. Blood Adv. 2017;1(19):1584\u20138.","journal-title":"Blood Adv."},{"issue":"12","key":"721_CR15","doi-asserted-by":"publisher","first-page":"E239","DOI":"10.1002\/ajh.23841","volume":"89","author":"P Langerbeins","year":"2014","unstructured":"Langerbeins P, Busch R, Anheier N, D\u00fcrig J, Bergmann M, Goebeler ME, et al. Poor efficacy and tolerability of R-CHOP in relapsed\/refractory chronic lymphocytic leukemia and Richter transformation. Am J Hematol. 2014;89(12):E239\u201343.","journal-title":"Am J Hematol"},{"key":"721_CR16","unstructured":"NCCN Clinical Practice Guidelines: histologic transformation (Richter\u2019s) and progression. Version 2.2023. Accessed August 18 Tvmracvotg, visit NCCN.org."},{"issue":"2","key":"721_CR17","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1200\/JCO.22.01028","volume":"41","author":"E Smyth","year":"2023","unstructured":"Smyth E, Eyre TA, Cheah CY. Emerging therapies for the management of Richter transformation. J Clin Oncol. 2023;41(2):395\u2013409.","journal-title":"J Clin Oncol"},{"issue":"2","key":"721_CR18","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/bjh.15035","volume":"180","author":"KA Rogers","year":"2018","unstructured":"Rogers KA, Huang Y, Ruppert AS, Salem G, Stephens DM, Heerema NA, et al. A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor. Br J Haematol. 2018;180(2):259\u201366.","journal-title":"Br J Haematol"},{"issue":"1","key":"721_CR19","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/s41375-020-0797-x","volume":"35","author":"O Al-Sawaf","year":"2021","unstructured":"Al-Sawaf O, Robrecht S, Bahlo J, Fink AM, Cramer P, v Tresckow J, et al. Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials. Leukemia. 2021;35(1):169\u201376.","journal-title":"Leukemia."},{"issue":"10","key":"721_CR20","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1007\/s00277-021-04603-y","volume":"100","author":"R Elnair","year":"2021","unstructured":"Elnair R, Ellithi M, Kallam A, Shostrom V, Bociek RG. Outcomes of Richter's transformation of chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): an analysis of the SEER database. Ann Hematol. 2021;100(10):2513\u20139.","journal-title":"Ann Hematol"},{"issue":"6","key":"721_CR21","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1111\/bjh.16748","volume":"190","author":"P Abrisqueta","year":"2020","unstructured":"Abrisqueta P, Delgado J, Alcoceba M, Oliveira AC, Loscertales J, Hern\u00e1ndez-Rivas JA, et al. Clinical outcome and prognostic factors of patients with Richter syndrome: real-world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC). Br J Haematol. 2020;190(6):854\u201363.","journal-title":"Br J Haematol"},{"issue":"3","key":"721_CR22","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1080\/10428194.2018.1498494","volume":"60","author":"HD Popp","year":"2019","unstructured":"Popp HD, Flach J, Brendel S, Ruppenthal S, Kleiner H, Seifarth W, et al. Accumulation of DNA damage and alteration of the DNA damage response in monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. Leuk Lymphoma. 2019;60(3):795\u2013804.","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"721_CR23","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.3324\/haematol.2020.256388","volume":"106","author":"DM Stephens","year":"2021","unstructured":"Stephens DM, Boucher K, Kander E, Parikh SA, Parry EM, Shadman M, et al. Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration. Haematologica. 2021;106(11):2845\u201352.","journal-title":"Haematologica."},{"issue":"10","key":"721_CR24","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1182\/blood-2014-12-610782","volume":"125","author":"M Tsang","year":"2015","unstructured":"Tsang M, Shanafelt TD, Call TG, Ding W, Chanan-Khan A, Leis JF, et al. The efficacy of ibrutinib in the treatment of Richter syndrome. Blood. 2015;125(10):1676\u20138.","journal-title":"Blood."},{"issue":"12","key":"721_CR25","doi-asserted-by":"publisher","first-page":"e912","DOI":"10.1016\/S2352-3026(21)00305-7","volume":"8","author":"TA Eyre","year":"2021","unstructured":"Eyre TA, Schuh A, Wierda WG, Brown JR, Ghia P, Pagel JM, et al. Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1\u20132 study. Lancet Haematol. 2021;8(12):e912\u2013e21.","journal-title":"Lancet Haematol"},{"key":"721_CR26","doi-asserted-by":"crossref","unstructured":"Al-Sawaf O, Robrecht S, Stumpf J, Fink A-M, Ritgen M, Johansson P, et al. The CLL-RT1 trial: a multicenter phase-2 trial of zanubrutinib, a BTK inhibitor, plus tislelizumab, a PD-1 inhibitor, for patients with Richter transformation. Hematol Oncol. 2021;39(S2).","DOI":"10.1002\/hon.161_2880"},{"issue":"1","key":"721_CR27","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1186\/s12885-019-5717-y","volume":"19","author":"N Appleby","year":"2019","unstructured":"Appleby N, Eyre TA, Cabes M, Jackson A, Boucher R, Yates F, et al. The STELLAR trial protocol: a prospective multicentre trial for Richter's syndrome consisting of a randomised trial investigation CHOP-R with or without acalabrutinib for newly diagnosed RS and a single-arm platform study for evaluation of novel agents in relapsed disease. BMC Cancer. 2019;19(1):471.","journal-title":"BMC Cancer"},{"issue":"9","key":"721_CR28","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","volume":"21","author":"O Al-Sawaf","year":"2020","unstructured":"Al-Sawaf O, Zhang C, Tandon M, Sinha A, Fink AM, Robrecht S, et al. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2020;21(9):1188\u2013200.","journal-title":"Lancet Oncol"},{"issue":"36","key":"721_CR29","doi-asserted-by":"publisher","first-page":"4049","DOI":"10.1200\/JCO.21.01181","volume":"39","author":"O Al-Sawaf","year":"2021","unstructured":"Al-Sawaf O, Zhang C, Lu T, Liao MZ, Panchal A, Robrecht S, et al. Minimal residual disease dynamics after venetoclax-obinutuzumab treatment: extended off-treatment follow-up from the randomized CLL14 study. J Clin Oncol. 2021;39(36):4049\u201360.","journal-title":"J Clin Oncol"},{"issue":"19","key":"721_CR30","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1200\/JCO.2017.76.6840","volume":"36","author":"S Stilgenbauer","year":"2018","unstructured":"Stilgenbauer S, Eichhorst B, Schetelig J, Hillmen P, Seymour JF, Coutre S, et al. Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial. J Clin Oncol. 2018;36(19):1973\u201380.","journal-title":"J Clin Oncol"},{"issue":"8","key":"721_CR31","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1182\/blood.2021015014","volume":"140","author":"JF Seymour","year":"2022","unstructured":"Seymour JF, Kipps TJ, Eichhorst BF, D\u2019Rozario J, Owen CJ, Assouline S, et al. Enduring undetectable MRD and updated outcomes in relapsed\/refractory CLL after fixed-duration venetoclax-rituximab. Blood. 2022;140(8):839\u201350.","journal-title":"Blood."},{"issue":"22","key":"721_CR32","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1182\/blood.2021014488","volume":"139","author":"CS Tam","year":"2022","unstructured":"Tam CS, Allan JN, Siddiqi T, Kipps TJ, Jacobs R, Opat S, et al. Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. Blood. 2022;139(22):3278\u201389.","journal-title":"Blood."},{"issue":"8","key":"721_CR33","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","volume":"35","author":"MS Davids","year":"2017","unstructured":"Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol. 2017;35(8):826\u201333.","journal-title":"J Clin Oncol"},{"issue":"5","key":"721_CR34","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1182\/blood.2021011386","volume":"139","author":"MS Davids","year":"2022","unstructured":"Davids MS, Rogers KA, Tyekucheva S, Wang Z, Pazienza S, Renner SK, et al. Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome. Blood. 2022;139(5):686\u20139.","journal-title":"Blood."},{"issue":"S2","key":"721_CR35","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1002\/hon.3164_343","volume":"41","author":"MS Davids","year":"2023","unstructured":"\u2022\u2022 Davids MS, Rogers KA, Jain N, Tyekucheva S, Ren Y, Carey C, et al. Initial results of a multicenter phase 2 study of venetoclax in combination with R-CHOP (VR-CHOP) for patients with Richter Syndrome. Hematol Oncol. 2023;41(S2):466\u20138. This trial showed impressive response rates combining venetoclax plus REPOCH, but due to safety concerns has been amended to only treat patients with venetoclax plus RCHOP. Updated results are pending.","journal-title":"Hematol Oncol"},{"issue":"Supplement_1","key":"721_CR36","doi-asserted-by":"publisher","first-page":"4279","DOI":"10.1182\/blood-2019-128305","volume":"134","author":"JN Allan","year":"2019","unstructured":"Allan JN, Bhavsar EB, Vaisitti T, Sarno V, Liu Y, Arruga F, et al. CD79b Expression in Richter's Transformation. Blood. 2019;134(Supplement_1):4279.","journal-title":"Blood."},{"issue":"10277","key":"721_CR37","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","volume":"397","author":"AR Mato","year":"2021","unstructured":"Mato AR, Shah NN, Jurczak W, Cheah CY, Pagel JM, Woyach JA, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study. Lancet. 2021;397(10277):892\u2013901.","journal-title":"Lancet."},{"key":"721_CR38","doi-asserted-by":"crossref","unstructured":"Lewis KL, Cheah CY. Non-covalent BTK inhibitors-the new BTKids on the block for B-cell malignancies. J Pers Med. 2021;11(8).","DOI":"10.3390\/jpm11080764"},{"issue":"Supplement 1","key":"721_CR39","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1182\/blood-2022-157058","volume":"140","author":"WG Wierda","year":"2022","unstructured":"Wierda WG, Lewis DJ, Ghia P, Shah NN, Coombs CC, Cheah CY, et al. Efficacy of pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in Richter transformation: results from the phase 1\/2 BRUIN study. Blood. 2022;140(Supplement 1):846\u20139.","journal-title":"Blood."},{"key":"721_CR40","doi-asserted-by":"publisher","first-page":"4298","DOI":"10.1182\/blood-2019-127260","volume":"134","author":"J Woyach","year":"2019","unstructured":"Woyach J, Stephens DM, Flinn IW, Bhat SA, Savage RE, Chai F, et al. Final results of phase 1, dose escalation study evaluating ARQ 531 in patients with relapsed or refractory B-cell lymphoid malignancies. Blood. 2019;134:4298.","journal-title":"Blood."},{"issue":"2","key":"721_CR41","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1016\/S2352-3026(18)30217-5","volume":"6","author":"A Younes","year":"2019","unstructured":"Younes A, Brody J, Carpio C, Lopez-Guillermo A, Ben-Yehuda D, Ferhanoglu B, et al. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1\/2a study. Lancet Haematol. 2019;6(2):e67\u201378.","journal-title":"Lancet Haematol"},{"issue":"10","key":"721_CR42","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1182\/bloodadvances.2022008790","volume":"7","author":"N Jain","year":"2023","unstructured":"Jain N, Senapati J, Thakral B, Ferrajoli A, Thompson P, Burger J, et al. A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL. Blood Adv. 2023;7(10):1958\u201366.","journal-title":"Blood Adv"},{"issue":"4","key":"721_CR43","doi-asserted-by":"publisher","first-page":"e870","DOI":"10.1097\/HS9.0000000000000870","volume":"7","author":"C Tam","year":"2023","unstructured":"Tam C, Munoz J, Cull G, Opat S, Allewelt H, Zhang X, et al. Zanubrutinib, alone and in combination with tislelizumab, for the treatment of Richter transformation of chronic lymphocytic leukemia. Hemasphere. 2023;7(4):e870.","journal-title":"Hemasphere."},{"issue":"16_suppl","key":"721_CR44","doi-asserted-by":"publisher","first-page":"7502","DOI":"10.1200\/JCO.2023.41.16_suppl.7502","volume":"41","author":"M Montillo","year":"2023","unstructured":"\u2022\u2022 Montillo M, Rossi D, Zinzani PL, Motta M, Gaidano G, Quaresmini G, et al. Results of MOLTO, a multicenter, open label, phase II clinical trial evaluating venetoclax, atezolizumab and obinutuzumab combination in Richter syndrome. J Clin Oncol. 2023;41(16_suppl):7502. This trial was recently presented at the ASCO national conference, with impressive response rates observed using immunotherapy in atezolizumab plus venetoclax.","journal-title":"J Clin Oncol"},{"key":"721_CR45","doi-asserted-by":"crossref","unstructured":"Heyman BM, Choi MY, Kipps TJ. Obinutuzumab, high-dose methylprednisolone (HDMP), and lenalidomide for the treatment of patients with Richter's syndrome. Cancers (Basel). 2022;14(24).","DOI":"10.3390\/cancers14246035"},{"issue":"4","key":"721_CR46","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1111\/bjh.16302","volume":"188","author":"TD Rodgers","year":"2020","unstructured":"Rodgers TD, Baran A, Reagan PM, Casulo C, Zent C, Evans A, et al. Efficacy of lenalidomide in high-risk diffuse large B-cell lymphoma. Br J Haematol. 2020;188(4):e33\u2013e6.","journal-title":"Br J Haematol"},{"issue":"5","key":"721_CR47","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1080\/13543784.2017.1313230","volume":"26","author":"G Itchaki","year":"2017","unstructured":"Itchaki G, Brown JR. Lenalidomide in the treatment of chronic lymphocytic leukemia. Expert Opin Investig Drugs. 2017;26(5):633\u201350.","journal-title":"Expert Opin Investig Drugs"},{"issue":"11","key":"721_CR48","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa1315226","volume":"370","author":"RR Furman","year":"2014","unstructured":"Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370(11):997\u20131007.","journal-title":"N Engl J Med"},{"issue":"23","key":"721_CR49","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1182\/blood-2018-05-850461","volume":"132","author":"IW Flinn","year":"2018","unstructured":"Flinn IW, Hillmen P, Montillo M, Nagy Z, Ill\u00e9s \u00c1, Etienne G, et al. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL\/SLL. Blood. 2018;132(23):2446\u201355.","journal-title":"Blood."},{"issue":"24","key":"721_CR50","doi-asserted-by":"publisher","first-page":"3378","DOI":"10.1182\/blood.2020010187","volume":"137","author":"A Iannello","year":"2021","unstructured":"Iannello A, Vitale N, Coma S, Arruga F, Chadburn A, Di Napoli A, et al. Synergistic efficacy of the dual PI3K-\u03b4\/\u03b3 inhibitor duvelisib with the Bcl-2 inhibitor venetoclax in Richter syndrome PDX models. Blood. 2021;137(24):3378\u201389.","journal-title":"Blood."},{"issue":"Supplement 1","key":"721_CR51","doi-asserted-by":"publisher","first-page":"9871","DOI":"10.1182\/blood-2022-169986","volume":"140","author":"CE Ryan","year":"2022","unstructured":"Ryan CE, Crombie JL, Tyekucheva S, McDonough MM, Montegaard JS, Kim AI, et al. Updated results from a phase I\/II study of duvelisib and venetoclax in patients with relapsed or refractory (R\/R) chronic lymphocytic leukemia (CLL) or Richter's syndrome (RS). Blood. 2022;140(Supplement 1):9871\u20132.","journal-title":"Blood."},{"issue":"Supplement 1","key":"721_CR52","doi-asserted-by":"publisher","first-page":"6633","DOI":"10.1182\/blood-2022-160157","volume":"140","author":"G Shouse","year":"2022","unstructured":"Shouse G, Siddiqi T, Popplewell LL, Muir A, Melgar I, Orand K, et al. A phase I trial of PI3K\u03b1\u03b4 inhibitor copanlisib in combination with nivolumab in patients with Richter's transformation (RT) or transformed non-Hodgkin lymphoma (tNHL). Blood. 2022;140(Supplement 1):6633\u20134.","journal-title":"Blood."},{"issue":"11","key":"721_CR53","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","volume":"127","author":"A Viardot","year":"2016","unstructured":"Viardot A, Goebeler ME, Hess G, Neumann S, Pfreundschuh M, Adrian N, et al. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma. Blood. 2016;127(11):1410\u20136.","journal-title":"Blood."},{"issue":"Supplement 1","key":"721_CR54","doi-asserted-by":"publisher","first-page":"6631","DOI":"10.1182\/blood-2022-159695","volume":"140","author":"R Guieze","year":"2022","unstructured":"Guieze R, Ysebaert L, Roos-Weil D, Fornecker L-M, Ferrant E, Molina L, et al. Blinatumomab for patients with Richter syndrome: final results of the phase 2 Blinart trial from the Filo group. Blood. 2022;140(Supplement 1):6631\u20132.","journal-title":"Blood."},{"issue":"Supplement 1","key":"721_CR55","doi-asserted-by":"publisher","first-page":"3570","DOI":"10.1182\/blood-2021-147467","volume":"138","author":"R Guieze","year":"2021","unstructured":"Guieze R, Ysebaert L, Roos-Weil D, Molina L, Fornecker LM, Aurran T, et al. Blinatumomab for patients with Richter's syndrome: a multicenter phase 2 trial from the Filo group. Blood. 2021;138(Supplement 1):3570.","journal-title":"Blood."},{"issue":"Supplement 1","key":"721_CR56","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1182\/blood-2022-158298","volume":"140","author":"AP Kater","year":"2022","unstructured":"Kater AP, Ye JC, Sandoval-Sus J, Bellido M, Christensen JH, Mato AR, et al. Subcutaneous epcoritamab in patients with Richter's syndrome: early results from phase 1b\/2 trial (EPCORE CLL-1). Blood. 2022;140(Supplement 1):850\u20131.","journal-title":"Blood."},{"issue":"16_suppl","key":"721_CR57","doi-asserted-by":"publisher","first-page":"7525","DOI":"10.1200\/JCO.2023.41.16_suppl.7525","volume":"41","author":"Y Karimi","year":"2023","unstructured":"Karimi Y, Ghesquieres H, Jurczak W, Cheah C, Clausen M, Lugtenburg P, et al. Effect of follow-up time on the ability of subcutaneous epcoritamab to induce deep and durable complete remissions in patients with relapsed\/refractory large B-cell lymphoma: Updated results from the pivotal EPCORE NHL-1 trial. J Clin Oncol. 2023;41(16_suppl):7525.","journal-title":"J Clin Oncol"},{"issue":"18","key":"721_CR58","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1200\/JCO.20.03175","volume":"39","author":"M Hutchings","year":"2021","unstructured":"Hutchings M, Morschhauser F, Iacoboni G, Carlo-Stella C, Offner FC, Sureda A, et al. Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial. J Clin Oncol. 2021;39(18):1959\u201370.","journal-title":"J Clin Oncol"},{"issue":"S2","key":"721_CR59","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/hon.3163_28","volume":"41","author":"C Carlo-Stella","year":"2023","unstructured":"\u2022\u2022 Carlo-Stella C, Hutchings M, Offner F, Mulvihill E, Relf J, Byrne B, et al. Glofitamab monotherapy induces durable complete remissions and has a manageable safety profile in patients with Richter\u2019s transformation. Hematol Oncol. 2023;41(S2):63\u20135. Bispecific antibodies are an exciting new treatment modality for NHL, in this study of patients with RT, the efficacy of this therapy shown is promising.","journal-title":"Hematol Oncol"},{"issue":"10","key":"721_CR60","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","volume":"22","author":"SJ Schuster","year":"2021","unstructured":"Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22(10):1403\u201315.","journal-title":"Lancet Oncol"},{"issue":"14","key":"721_CR61","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1182\/blood.2022018730","volume":"141","author":"JS Abramson","year":"2023","unstructured":"Abramson JS, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, et al. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood. 2023;141(14):1675\u201384.","journal-title":"Blood."},{"issue":"19","key":"721_CR62","doi-asserted-by":"publisher","first-page":"4648","DOI":"10.1182\/bloodadvances.2020002783","volume":"4","author":"AS Kittai","year":"2020","unstructured":"Kittai AS, Bond DA, William B, Saad A, Penza S, Efebera Y, et al. Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome. Blood Adv. 2020;4(19):4648\u201352.","journal-title":"Blood Adv"},{"key":"721_CR63","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1182\/blood-2020-138904","volume":"136","author":"O Benjamini","year":"2020","unstructured":"Benjamini O, Shimoni A, Besser M, Shem-Tov N, Danylesko I, Yerushalmi R, et al. Safety and efficacy of CD19-CAR T cells in Richter's transformation after targeted therapy for chronic lymphocytic leukemia. Blood. 2020;136:40.","journal-title":"Blood."},{"key":"721_CR64","doi-asserted-by":"publisher","first-page":"828471","DOI":"10.3389\/fonc.2022.828471","volume":"12","author":"V Ortiz-Maldonado","year":"2022","unstructured":"Ortiz-Maldonado V, Frigola G, Espa\u00f1ol-Rego M, Balagu\u00e9 O, Mart\u00ednez-Cibri\u00e1n N, Magnano L, et al. Results of ARI-0001 CART19 cells in patients with chronic lymphocytic leukemia and Richter\u2019s transformation. Front Oncol. 2022;12:828471.","journal-title":"Front Oncol"},{"issue":"10254","key":"721_CR65","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839\u201352.","journal-title":"Lancet."},{"issue":"26","key":"721_CR66","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","volume":"35","author":"CJ Turtle","year":"2017","unstructured":"Turtle CJ, Hay KA, Hanafi LA, Li D, Cherian S, Chen X, et al. Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib. J Clin Oncol. 2017;35(26):3010\u201320.","journal-title":"J Clin Oncol"},{"issue":"18","key":"721_CR67","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1200\/JCO.2011.37.4108","volume":"30","author":"K Cwynarski","year":"2012","unstructured":"Cwynarski K, van Biezen A, de Wreede L, Stilgenbauer S, Bunjes D, Metzner B, et al. Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter's syndrome): a retrospective analysis from the chronic lymphocytic leukemia subcommittee of the chronic leukemia working party and lymphoma working party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2012;30(18):2211\u20137.","journal-title":"J Clin Oncol"},{"issue":"12","key":"721_CR68","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1016\/j.bbmt.2016.09.013","volume":"22","author":"MA Kharfan-Dabaja","year":"2016","unstructured":"Kharfan-Dabaja MA, Kumar A, Hamadani M, Stilgenbauer S, Ghia P, Anasetti C, et al. Clinical practice recommendations for use of allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia on behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2016;22(12):2117\u201325.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"721_CR69","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.hemonc.2020.05.002","volume":"14","author":"S Aulakh","year":"2021","unstructured":"Aulakh S, Reljic T, Yassine F, Ayala E, Chavez JC, Chanan-Khan A, et al. Allogeneic hematopoietic cell transplantation is an effective treatment for patients with Richter syndrome: A systematic review and meta-analysis. Hematol Oncol Stem Cell Ther. 2021;14(1):33\u201340.","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"12","key":"721_CR70","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.3324\/haematol.2021.279033","volume":"106","author":"HT Kim","year":"2021","unstructured":"Kim HT, Baker PO, Parry E, Davids M, Alyea EP, Ho VT, et al. Allogeneic hematopoietic cell transplantation outcomes in patients with Richter's transformation. Haematologica. 2021;106(12):3219\u201322.","journal-title":"Haematologica."},{"issue":"18","key":"721_CR71","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.1182\/bloodadvances.2021004865","volume":"5","author":"AF Herrera","year":"2021","unstructured":"Herrera AF, Ahn KW, Litovich C, Chen Y, Assal A, Bashir Q, et al. Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndrome. Blood Adv. 2021;5(18):3528\u201339.","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"721_CR72","doi-asserted-by":"publisher","first-page":"6640","DOI":"10.1182\/blood-2022-163509","volume":"140","author":"SE Spurgeon","year":"2022","unstructured":"Spurgeon SE, Mei M, Barr PM, Barrientos JC, de Vos S, Furman RR, et al. Waveline-001: updated results from a phase 1 dose escalation and cohort expansion study of zilovertamab vedotin (MK-2140) in non-Hodgkin lymphoma. Blood. 2022;140(Supplement 1):6640\u20131.","journal-title":"Blood."},{"issue":"Supplement 1","key":"721_CR73","doi-asserted-by":"publisher","first-page":"5384","DOI":"10.1182\/blood-2018-99-112944","volume":"132","author":"SF Huntington","year":"2018","unstructured":"Huntington SF, Schuster SJ, He W, Shen T, Walker H, Leary L, et al. Phase I study of first-in-class oral triplet therapy DTRM-555 in relapsed\/refractory lymphoma patients through fixed-dose combination and synthetic lethality. Blood. 2018;132(Supplement 1):5384.","journal-title":"Blood."},{"key":"721_CR74","doi-asserted-by":"crossref","unstructured":"Sharp A, Williams A, Blagden S, Plummer R, Hochhauser D, Krebs MG, et al. PB2099: A first-in-human phase 1 trial of NX-1607, a first-in-class oral CBL-B inhibitor, in patients with advanced malignancies including Richter transformation DLBCL. Hemasphere. 2022;6.","DOI":"10.1097\/01.HS9.0000851228.41662.2b"},{"issue":"Supplement 1","key":"721_CR75","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1182\/blood-2022-158998","volume":"140","author":"N Bhagwat","year":"2022","unstructured":"Bhagwat N, Ruggeri B, Zhang Y, Mosesson Y, Killick-Cole C, Jagannathan V, et al. PRT2527, a novel highly selective cyclin-dependent kinase 9 (CDK9) inhibitor, has potent anti-leukemic activity in preclinical primary models of human B-ALL, T-ALL, and CLL. Blood. 2022;140(Supplement 1):505\u20136.","journal-title":"Blood."},{"key":"721_CR76","doi-asserted-by":"crossref","unstructured":"Mandal R, Becker S, Strebhardt K. Targeting CDK9 for anti-cancer therapeutics. Cancers (Basel). 2021;13(9)","DOI":"10.3390\/cancers13092181"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-023-00721-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-023-00721-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-023-00721-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T10:06:19Z","timestamp":1708941979000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-023-00721-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,9]]},"references-count":76,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["721"],"URL":"https:\/\/doi.org\/10.1007\/s11899-023-00721-8","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,9]]},"assertion":[{"value":"24 December 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"A.B., and A.H. have no disclosures. A.S.K. receives research funding from AstraZeneca and BeiGene, and\u00a0\u00a0has consulted for Abbvie, AstraZeneca, Beigene, BMS, Kite a Gilead company, Janssen, and Lilly@Loxo,\u00a0\u00a0and is on the speaker\u2019s bureau for BeiGene.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}